Search Results 1571-1580 of 21918 for Inhibition
Current use of CYP 3A4 inhibitors. These include Clarithromycin, HIV protease inhibitors, Itraconazole, grapefruit juice, Cyclosporine, Rifampin or Digoxin ...
The novel brain penetrant ATM inhibitor WSD0628 provides robust radiosensitization of brain tumor patient derived xenografts. ... inhibitors. Radiother ...
Medicare certified; Licensed by Minnesota; Accredited by The Joint Commission; Provider member of the Minnesota Network of Hospice & Palliative Care; Provider ...
... inhibitor or a mammalian target of rapamycin (mTOR) inhibitor. * Systemic chemotherapy and any liver-directed or other ablative therapy within 4 weeks ...
Radisky's research team is working to develop new, more-selective drugs based on the tissue inhibitors of metalloproteinases (TIMPs), natural human proteins ...
* Systemic treatment with ruxolitinib or any other JAK inhibitor within 7 days of study entry * Prior use of ruxolitinib to treat GVHD at any time * ...
Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin, ciprofloxacin), strong inhibitors of CYP3A (clarithromycin, telithromycin ...
... inhibitors], antipsychotics, opiates, GABAergic agents and benzodiazepines). Note: Tricyclic antidepressants are permissible at doses equal to or less than ...
Developing a new drug for women with resistance to aromatase inhibitors; Identifying mechanisms for why some people do not respond to endocrine treatment ...
... inhibition across cancer types. Similarly, loss of KDM6A activity can lead to increased sensitivity to bromodomain and extra terminal (BET) inhibitors. In ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!